Lv31
344 积分 2023-01-09 加入
Better pre-transplant treatment options for TP53-mutated MDS: cytoreductive or non-cytoreductive therapy?
5小时前
待确认
Relationship between age, conditioning intensity, and outcome after allografting in adults age ≥60 years with AML
2个月前
已完结
Allogeneic hematopoietic stem cell transplantation in elderly patients with AML and MDS: navigating risks and optimizing outcomes
2个月前
已完结
A temporal and multinational assessment of acute myeloid leukemia (AML) cancer incidence, survival, and disease burden
2个月前
已完结
Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional Database
3个月前
已完结
Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation
3个月前
已完结
Allogeneic hematopoietic stem cell transplantation in elderly patients with AML and MDS: navigating risks and optimizing outcomes
3个月前
已完结
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial
3个月前
已完结
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
4个月前
已完结
皖公网安备34019202002308
